Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.53 |
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926818 | 1.00 | CDK2 (0.54) | CDK2LNPEPHPGDSERAP2PYGL | |
| SCHEMBL5926278 | 0.91 | PYGL (0.55) | CDK2LNPEPPYGLKDRERAP1 | |
| SCHEMBL3974510 | 0.85 | PYGL (0.50) | CDK2LNPEPPYGLHDAC1HDAC6 | |
| SCHEMBL3974514 | 0.85 | PYGL (0.50) | CDK2LNPEPPYGLHDAC1HDAC6 | |
| SCHEMBL3995599 | 0.84 | PSMB5 (0.51) | CDK2LNPEPERAP2PYGLKDR | |
| SCHEMBL3980063 | 0.83 | LNPEP (0.54) | CDK2LNPEPERAP2PYGLKDR | |
| SCHEMBL3979425 | 0.83 | LNPEP (0.54) | CDK2LNPEPERAP2PYGLKDR | |
| SCHEMBL5691968 | 0.82 | CDK2 (0.45) | CDK2LNPEPHPGDSPYGLHDAC1 | |
| SCHEMBL3989390 | 0.82 | TACR3 (0.44) | HPGDS | |
| SCHEMBL5926515 | 0.81 | LNPEP (0.46) | CDK2LNPEPERAP2PYGLERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | CDK2 1163/4885LNPEP 788/4885HPGDS 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.